AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36759901
Drug: Rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation therapy only
Trial: 36759902
Drug: INTERCARE intervention
RxNorm normalized name: Ivercare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INTERCARE intervention with low fidelity to communication tools (e.g., ISBAR)
Trial: 36760605
Drug: 0.6% compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6% compound lidocaine hydrochloride injection
Trial: 36760794
Drug: S1 rTMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S1 rTMS and SS alone or in combination
Trial: 36760794
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of S1 rTMS and SS
Trial: 36761900
Drug: Intranasal photodynamic
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal photodynamic therapy (PDT)
Trial: 36762424
Drug: Peak hsTnI
RxNorm normalized name: PEAK FLOW METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak hsTnI <75 ng/L
Trial: 36762424
Drug: Peak hsTnI
RxNorm normalized name: PEAK FLOW METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak hsTnI 75 ng/L to <1000 ng/L
Trial: 36762424
Drug: Peak hsTnI
RxNorm normalized name: PEAK FLOW METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak hsTnI ≥1000 ng/L
Trial: 36762424
Drug: Peak hsTnI
RxNorm normalized name: PEAK FLOW METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak hsTnI ≥75 ng/L
Trial: 36762424
Drug: Peak hsTnI
RxNorm normalized name: PEAK FLOW METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak hsTnI ≥75 ng/L with ischemic features
Trial: 36762424
Drug: Peak hsTnI
RxNorm normalized name: PEAK FLOW METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak hsTnI ≥75 ng/L without ischemic features
Trial: 36762782
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus for 6 months
Trial: 36762930
Drug: gp120-reactive monoclonal
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp120-reactive monoclonal antibodies (mAbs) isolated from participants
Trial: 36762930
Drug: Vaccine-induced gp120-specific
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-induced gp120-specific antibody lineages
Trial: 36763183
Drug: 12-week web-based
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week web-based dietary intervention with daily text messages
Trial: 36763307
Drug: Extended interval
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended interval dosing (EID) of natalizumab (≤ 9 infusions/year)
Trial: 36763307
Drug: Standard interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard interval dosing (SID) of natalizumab (≥ 11 infusions/year)
Trial: 36763307
Drug: Extended interval
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended interval dosing (EID)
Trial: 36763307
Drug: Standard interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard interval dosing (SID)
Trial: 36763327
Drug: Acoziborole (20-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acoziborole (20-1200 mg single oral dose)
Trial: 36763327
Drug: Capsules versus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules versus tablets (in additional cohorts)
Trial: 36763327
Drug: 960-mg tablet
RxNorm normalized name: hydrotalcite 960 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 960-mg tablet cohort (in additional cohorts)
Trial: 36763359
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser therapy (CLT)
Trial: 36763358
Drug: Enoxaparin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (1 mg/kg subcutaneous twice daily)
Trial: 36763537
Drug: KPd (carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KPd (carfilzomib 20/27 mg/m2, pomalidomide 4 mg, dexamethasone 40 mg)
Trial: 36763879
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg (continuous dosing)
Trial: 36763879
Drug: Baricitinib 2
RxNorm normalized name: baricitinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 2 mg (downtitration)
Trial: 36763879
Drug: Placebo (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (treatment withdrawal, 4-mg cohort)
Trial: 36763879
Drug: Baricitinib 2
RxNorm normalized name: baricitinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 2 mg (continuous dosing)
Trial: 36763879
Drug: Baricitinib 1
RxNorm normalized name: baricitinib 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 1 mg (downtitration)
Trial: 36763879
Drug: Placebo (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (treatment withdrawal, 2-mg cohort)
Trial: 36763879
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg (downtitration)
Trial: 36763879
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg (treatment withdrawal)
Trial: 36763879
Drug: Baricitinib 2
RxNorm normalized name: baricitinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 2 mg (treatment withdrawal)
Trial: 36763899
Drug: OnabotulinumtoxinA (ONA)
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA (ONA) injections (1.5 U/injection site)
Trial: 36763919
Drug: Intravaginal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal treatment with gel containing 600 IU/mL of oxytocin
Trial: 36763919
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (gel alone)
Trial: 36764323
Drug: CYAD-01 (autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYAD-01 (autologous NKG2D-based CAR T-cell therapy)
Trial: 36764326
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg acute treatment (n=19)
Trial: 36764326
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg twice daily for 3 weeks (n=16)
Trial: 36764326
Drug: Placebo acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo acute treatment (n=12)
Trial: 36765309
Drug: Intervention components
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention components to support PWIDLH to reduce drug use and improve mental health and engagement in HIV care.
Trial: 36765312
Drug: KopOpOuders-PTSD (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KopOpOuders-PTSD (treatment as usual + intervention)
Trial: 36765318
Drug: Oral arsenic
RxNorm normalized name: arsenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral arsenic trioxide (oral-ATO)-based regimens
Trial: 36765332
Drug: Suprachoroidal injection
RxNorm normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprachoroidal injection of 4 mg Triamcinolone Acetonide (TA)
Trial: 36765421
Drug: Low-dose alteplase
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alteplase infusion (24 h)
Trial: 36765556
Drug: Calcium electroporation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium electroporation treatment
Trial: 36765803
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for primary tumors of the spine
Trial: 36769445
Drug: Low-dose radiotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiotherapy (0.5 Gy)
Trial: 36769543
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (first 4 weeks)
Trial: 36769813
Drug: Traditional logistic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional logistic regression and eleven ML algorithms
Trial: 36771199
Drug: Resveratrol supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol supplement
Trial: 36772985
Drug: Trauma plasma-derived
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma plasma-derived exosomes (100 μg and 200 μg)
Trial: 36772985
Drug: Trauma plasma-derived
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma plasma-derived exosomes (50 μg)
Trial: 36772985
Drug: Trauma exosomal
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma exosomal protein (100 μg) with bone marrow stromal cells
Trial: 36773112
Drug: Ceftolozane/tazobactam 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane/tazobactam 3 g every 8 h for 8-14 days
Trial: 36773112
Drug: Meropenem 1
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1 g every 8 h for 8-14 days
Trial: 36774112
Drug: Herbs and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbs and spices at doses of 0.5, 3.3, and 6.6 g/day
Trial: 36774905
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine at a dose of 6 mg/kg
Trial: 36774933
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg IV every 2 weeks for 12 doses) plus Ipilimumab (1 mg/kg IV every 6 weeks for four doses)
Trial: 36775009
Drug: Fitbit Charge
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fitbit Charge 5 and daily text messages
Trial: 36775980
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment with cardioprotective antidiabetic medication
Trial: 36777769
Drug: Capecitabine maintenance
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine maintenance therapy plus best supportive care (CBSC)
Trial: 36778595
Drug: Nutraceutical supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical supplements with yeast β-glucan, prebiotics, minerals
Trial: 36778864
Drug: Anakinra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100 mg subcutaneously every 12 hours for 3 days, then 100 mg subcutaneously once daily for 4 days) in addition to standard of care (SOC)
Trial: 36779003
Drug: Activity monitor
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity monitor (Fitbit Charge 3) and custom weekly surveys
Trial: 36779325
Drug: Hodgkin lymphoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hodgkin lymphoma treatment
Trial: 36779512
Drug: Magrolimab in
RxNorm normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magrolimab in combination with commonly used myeloma therapies
Trial: 36779614
Drug: Aragonite-based osteochondral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aragonite-based osteochondral implant
Trial: 36780159
Drug: SER-109 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER-109 (4 capsules daily for 3 days after symptom resolution following antibiotic treatment)
Trial: 36780180
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU per day of oral vitamin D3 supplementation
Trial: 36780180
Drug: 400 IU
RxNorm normalized name: Vitamin D 400 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU per day of oral vitamin D3 supplementation
Trial: 36780265
Drug: Effective Skills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective Skills to Empower Effective Men (ESTEEM); an LGBQ-affirmative transdiagnostic cognitive behavioral therapy (CBT)
Trial: 36780610
Drug: T-DXd 5.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-DXd 5.4 mg/kg intravenously once every 3 weeks (n = 373)
Trial: 36780610
Drug: Physicians' choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physicians' choice of chemotherapy (n = 184)
Trial: 36780675
Drug: Difelikefalin 2
RxNorm normalized name: DIFELIKEFALIN
DrugBank: Difelikefalin (DB11938)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Difelikefalin 2 mg orally twice daily for 8 weeks
Trial: 36780676
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon lambda (single subcutaneous injection, 180 μg)
Trial: 36780676
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single injection or oral)
Trial: 36780768
Drug: Medication Treatment
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Treatment for Opioid Use Disorder (MOUD) strategies
Trial: 36781334
Drug: SCB-2019 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCB-2019 (two doses administered intramuscularly 21 days apart)
Trial: 36781334
Drug: SCB-2019 (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCB-2019 (one dose administered)
Trial: 36781469
Drug: Pronase administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pronase administration
Trial: 36781469
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no pronase administration)
Trial: 36781774
Drug: Plerixafor-based hematopoietic
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor-based hematopoietic cell mobilization combined with granulocyte-colony stimulating factor (G-CSF)
Trial: 36781928
Drug: Sarpogrelate plus
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate plus aspirin (300 mg orally once per day for 6 months)
Trial: 36781928
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (75 mg orally once per day for 6 months)
Trial: 36782093
Drug: Sotagliflozin 200
RxNorm normalized name: sotagliflozin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotagliflozin 200 mg and 400 mg
Trial: 36782134
Drug: Colorectal cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorectal cancer survivors' recollections of their illness and treatment experiences after therapy
Trial: 36782325
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (1500 mg once weekly for 8 weeks)
Trial: 36785526
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of antibiotic therapy (ofloxacin or third-generation cephalosporin)
Trial: 36785526
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of antibiotic therapy (ofloxacin or third-generation cephalosporin)
Trial: 36785850
Drug: Two-dose PCV10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose PCV10 schedule (2,6 months)
Trial: 36785850
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no infant doses of PCV)
Trial: 36786049
Drug: Changing infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Changing infusion set every 0-4 days
Trial: 36786049
Drug: Timing insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Timing insulin 10-15 min before meal
Trial: 36786322
Drug: Medication-overuse headache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-overuse headache patients
Trial: 36787013
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical management plus ReActiv8® restorative neurostimulation therapy
Trial: 36787089
Drug: INCB062079 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB062079 15 mg twice daily
Trial: 36787089
Drug: INCB062079 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB062079 10 mg once daily
Trial: 36787124
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diuretics with varying pharmacological targets for diuretic resistance and sodium avidity
Trial: 36787124
Drug: Invasive decongestion
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive decongestion methods including ultrafiltration or kidney replacement therapy (KRT) such as peritoneal dialysis
Trial: 36787235
Drug: Mindfulness-based music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based music therapy intervention (4 sessions, 45 minutes each over 12 weeks)
Trial: 36787249
Drug: Mosaic vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosaic vaccine
Trial: 36787249
Drug: CON-S vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CON-S vaccine
Trial: 36787249
Drug: Nat-B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nat-B vaccine
Trial: 36787305
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg/day orally for 7 days
Trial: 36787525
Drug: Estradiol cream
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol cream 50 μg
Trial: 36787525
Drug: Estradiol cream
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol cream 100 μg
Trial: 36788081
Drug: Short-term preoperative
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term preoperative endocrine therapy (pET; tamoxifen or aromatase inhibitor)
Trial: 36788511
Drug: Topical TAC
RxNorm normalized name: triamcinolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TAC 0.1% patch twice daily
Trial: 36788511
Drug: Topical TAC
RxNorm normalized name: triamcinolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TAC 0.1% gel
Trial: 36788511
Drug: Topical TRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TRI 0.1% gel four times daily
Trial: 36789515
Drug: Cariprazine 1.5
RxNorm normalized name: cariprazine 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 1.5 mg/day and 3.0 mg/day
Trial: 36789577
Drug: Fexuprazan 20
RxNorm normalized name: fexuprazan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexuprazan 20 mg once a day (q.d.)
Trial: 36789577
Drug: Fexuprazan 10
RxNorm normalized name: fexuprazan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexuprazan 10 mg twice a day (b.i.d.)
Trial: 36789614
Drug: Antiplatelet agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agent
Trial: 36789614
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant vs. antiplatelet agent
Trial: 36789945
Drug: FeFum+GOS (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FeFum+GOS (5.0 mg iron with 3.0 g GOS)
Trial: 36789945
Drug: FeFum+HMO (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FeFum+HMO (5.0 mg iron with 3.0 g HMO)
Trial: 36789945
Drug: FeFum (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FeFum (5.0 mg iron without GOS or HMO)
Trial: 36790457
Drug: High intake
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intake of total meat (≥ 108.57 g/day)
Trial: 36790457
Drug: High intake
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intake of red/processed meat (≥ 74.29 g/day)
Trial: 36790457
Drug: High intake
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intake of protein (≥ 65.05 g/day)
Trial: 36790457
Drug: High intake
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intake of dietary iron (≥ 8.58 mg/day)
Trial: 36790596
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg metformin with 10 mg baxdrostat
Trial: 36790596
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg metformin alone
Trial: 36790672
Drug: Low-level red-light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level red-light (RLRL) therapy